Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Medical Research Journal
MENU
Shortcuts Submit an article Author Guidelines Reviewers 2023 Focus and Scope

open access

Vol 7, No 3 (2022)
Original article
Published online: 2022-08-09
View PDF Download PDF file
Get Citation

Evaluation of the associations between GDF-15, OPG, and IL-15 levels in CRC: preliminary results

Julia Robotycka1, Sylwia Mielcarska1, Miriam Dawidowicz1, Agnieszka Kula1, Błażej Ochman1, Tomasz Niebudek1, Bogumiła Strzałkowska1, Dariusz Waniczek2, Elżbieta Świętochowska1
DOI: 10.5603/MRJ.a2022.0037
·
Medical Research Journal 2022;7(3):208-214.
Affiliations
  1. Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze, Poland
  2. Department of Oncological Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

open access

Vol 7, No 3 (2022)
ORIGINAL ARTICLES
Published online: 2022-08-09

Abstract

Introduction: Osteoprotegerin (OPG), Interleukin-15 (IL-15), and Growth/Differentiation Factor-15 (GDF-15) are all proven to take part in the processes associated with colorectal carcinoma (CRC) including tissue remodeling, inflammation modulation, and metastasis. Aim of the study: To investigate the concentrations of GDF-15, OPG and IL-15 in tumor and margin tissues of CRC in relation to clinicopathological features of patients.

Material and methods: The study used 50 specimens of tumor and tumor-free margin tissues obtained from CRC patients. To determine the GDF-15, OPG and IL-15 concentrations commercially available enzyme-linked immunosorbent assay (ELISA) kits were used.

Results: Concentrations of GDF-15, OPG and IL-15 were significantly higher in the tumor in comparison with the margin. The tumor levels of GDF-15 were positively associated with those of OPG and IL-15, while tumor levels of OPG correlated positively with those of IL-15. There was no association between levels of investigated molecules and clinical features of patients.

Conclusions: The levels of GDF-15, OPG and IL-15 are elevated in patients suffering from CRC. More studies are needed to establish a specific role of these cytokines in the development, tumor growth, progression, and prognosis of CRC and to examine their role as possible CRC treatment candidates.

Abstract

Introduction: Osteoprotegerin (OPG), Interleukin-15 (IL-15), and Growth/Differentiation Factor-15 (GDF-15) are all proven to take part in the processes associated with colorectal carcinoma (CRC) including tissue remodeling, inflammation modulation, and metastasis. Aim of the study: To investigate the concentrations of GDF-15, OPG and IL-15 in tumor and margin tissues of CRC in relation to clinicopathological features of patients.

Material and methods: The study used 50 specimens of tumor and tumor-free margin tissues obtained from CRC patients. To determine the GDF-15, OPG and IL-15 concentrations commercially available enzyme-linked immunosorbent assay (ELISA) kits were used.

Results: Concentrations of GDF-15, OPG and IL-15 were significantly higher in the tumor in comparison with the margin. The tumor levels of GDF-15 were positively associated with those of OPG and IL-15, while tumor levels of OPG correlated positively with those of IL-15. There was no association between levels of investigated molecules and clinical features of patients.

Conclusions: The levels of GDF-15, OPG and IL-15 are elevated in patients suffering from CRC. More studies are needed to establish a specific role of these cytokines in the development, tumor growth, progression, and prognosis of CRC and to examine their role as possible CRC treatment candidates.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

colorectal cancer (CRC), growth/differentiation factor-15 (GDF-15), osteoprotegerin (OPG), interleukin-15 (IL-15)

About this article
Title

Evaluation of the associations between GDF-15, OPG, and IL-15 levels in CRC: preliminary results

Journal

Medical Research Journal

Issue

Vol 7, No 3 (2022)

Article type

Original article

Pages

208-214

Published online

2022-08-09

Page views

3855

Article views/downloads

296

DOI

10.5603/MRJ.a2022.0037

Bibliographic record

Medical Research Journal 2022;7(3):208-214.

Keywords

colorectal cancer (CRC)
growth/differentiation factor-15 (GDF-15)
osteoprotegerin (OPG)
interleukin-15 (IL-15)

Authors

Julia Robotycka
Sylwia Mielcarska
Miriam Dawidowicz
Agnieszka Kula
Błażej Ochman
Tomasz Niebudek
Bogumiła Strzałkowska
Dariusz Waniczek
Elżbieta Świętochowska

References (26)
  1. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021; 14(10): 101174.
    CrossRefPubMed
  2. Johnson CM, Wei C, Ensor JE, et al. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 2013; 24(6): 1207–1222.
    CrossRefPubMed
  3. Amersi F, Agustin M, Ko CY. Colorectal cancer: epidemiology, risk factors, and health services. Clin Colon Rectal Surg. 2005; 18(3): 133–140.
    CrossRefPubMed
  4. Sammarco G, Gallo G, Vescio G, et al. Mast cells, microRNAs and others: the role of translational research on colorectal cancer in the forthcoming era of precision medicine. J Clin Med. 2020; 9(9).
    CrossRefPubMed
  5. Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019; 16(12): 713–732.
    CrossRefPubMed
  6. Hsiao EC, Koniaris LG, Zimmers-Koniaris T, et al. Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol. 2000; 20(10): 3742–3751.
    CrossRefPubMed
  7. Li C, Wang X, Casal I, et al. Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer. J Cell Mol Med. 2016; 20(8): 1420–1426.
    CrossRefPubMed
  8. Bondurant KL, Lundgreen A, Herrick JS, et al. Interleukin genes and associations with colon and rectal cancer risk and overall survival. Int J Cancer. 2013; 132(4): 905–915.
    CrossRefPubMed
  9. Tsuruda T. Osteoprotegerin: osteo-vascular connection. J Atheroscler Thromb. 2015; 22(3): 233–234.
    CrossRefPubMed
  10. Rochette L, Meloux A, Rigal E, et al. The role of osteoprotegerin and its ligands in vascular function. Int J Mol Sci. 2019; 20(3).
    CrossRefPubMed
  11. Tsukamoto S, Ishikawa T, Iida S, et al. Clinical significance of osteoprotegerin expression in human colorectal cancer. Clin Cancer Res. 2011; 17(8): 2444–2450.
    CrossRefPubMed
  12. Guo J, Liang Y, Xue D, et al. Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity. Cell Res. 2021; 31(11): 1190–1198.
    CrossRefPubMed
  13. Wang Y, Jiang T, Jiang M, et al. Appraising growth differentiation factor 15 as a promising biomarker in digestive system tumors: a meta-analysis. BMC Cancer. 2019; 19(1): 177.
    CrossRefPubMed
  14. Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clin Sci (Lond). 2006; 110(3): 279–291.
    CrossRefPubMed
  15. McGonigle JS, Giachelli CM, Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis. 2009; 12(1): 35–46.
    CrossRefPubMed
  16. Cross SS, Yang Z, Brown NJ, et al. Osteoprotegerin (OPG) - a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer. 2006; 118(8): 1901–1908.
    CrossRefPubMed
  17. Kim HS, Yoon G, Do SI, et al. Down-regulation of osteoprotegerin expression as a novel biomarker for colorectal carcinoma. Oncotarget. 2016; 7(12): 15187–15199.
    CrossRefPubMed
  18. Pettersen I, Bakkelund W, Smedsrød B. Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res. 2005; 25(6B): 3809–3816.
    PubMed
  19. Liu X, Li Y, Sun X, et al. Powerful anti-colon cancer effect of modified nanoparticle-mediated IL-15 immunogene therapy through activation of the host immune system. Theranostics. 2018; 8(13): 3490–3503.
    CrossRefPubMed
  20. Geerts D, Chopra C, Connelly L. Osteoprotegerin: relationship to breast cancer risk and prognosis. Front Oncol. 2020; 10: 462.
    CrossRefPubMed
  21. De Toni EN, Nagel D, Philipp AB, et al. Correlation between baseline osteoprotegerin serum levels and prognosis of advanced-stage colorectal cancer patients. Cell Physiol Biochem. 2018; 45(2): 605–613.
    CrossRefPubMed
  22. Rocca YS, Roberti MP, Juliá EP, et al. Phenotypic and functional dysregulated blood NK cells in colorectal cancer patients can be activated by cetuximab plus il-2 or IL-15. Front Immunol. 2016; 7: 413.
    CrossRefPubMed
  23. Bahri R, Pateras IS, D'Orlando O, et al. IL-15 suppresses colitis-associated colon carcinogenesis by inducing antitumor immunity. Oncoimmunology. 2015; 4(9): e1002721.
    CrossRefPubMed
  24. Wallin U, Glimelius B, Jirström K, et al. Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer. Br J Cancer. 2011; 104(10): 1619–1627.
    CrossRefPubMed
  25. Vocka M, Langer D, Fryba V, et al. Growth/differentiation factor 15 (GDF-15) as new potential serum marker in patients with metastatic colorectal cancer. Cancer Biomark. 2018; 21(4): 869–874.
    CrossRefPubMed
  26. Li C, Wang J, Kong J, et al. GDF15 promotes EMT and metastasis in colorectal cancer. Oncotarget. 2016; 7(1): 860–872.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl